Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24468312 | 1.00 | LMNA (0.40) | LMNAKMT2AAAK1MMP13SOS1 | |
| SCHEMBL30912465 | 0.80 | IRAK4 (0.41) | LMNAKMT2AAAK1MMP13SOS1 | |
| SCHEMBL30912458 | 0.80 | IRAK4 (0.41) | LMNAKMT2AAAK1MMP13SOS1 | |
| SCHEMBL30912463 | 0.80 | IRAK4 (0.41) | LMNAKMT2AAAK1MMP13SOS1 | |
| SCHEMBL16837680 | 0.76 | AAK1 (0.43) | LMNAAAK1SOS1 | |
| SCHEMBL29685934 | 0.75 | CASP1 (0.36) | LMNAKMT2AAAK1NPC1SMN1; SMN2 | |
| SCHEMBL24468313 | 0.75 | CASP1 (0.36) | LMNAKMT2AAAK1NPC1SMN1; SMN2 | |
| SCHEMBL23318417 | 0.75 | ALOX5 (0.49) | LMNAKMT2AAAK1MMP13NPC1 | |
| SCHEMBL22946389 | 0.75 | ALOX5 (0.49) | LMNAKMT2AAAK1MMP13NPC1 | |
| SCHEMBL29531722 | 0.75 | ALOX5 (0.49) | LMNAKMT2AAAK1MMP13NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251624-B1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. | 2024-03-28 | — | — | US | disclosed |
| EP-4251624-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | Amgen, Inc (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2022115377-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | LMNA 2705/4885KMT2A 41/4885AAK1 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.